Biocryst Pharmaceuticals Stock
Biocryst Pharmaceuticals Stock
A loss of -1.220% shows a downward development for Biocryst Pharmaceuticals.
Biocryst Pharmaceuticals is currently one of the favorites of our community with 8 Buy predictions and no Sell predictions.
With a target price of 10 € there is potential for a 142.66% increase which would mean more than doubling the current price of 4.12 € for Biocryst Pharmaceuticals.
So far the community has only identified positive things for Biocryst Pharmaceuticals stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Biocryst Pharmaceuticals in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Biocryst Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Biocryst Pharmaceuticals | -1.220% | 6.102% | -5.720% | -45.083% | -25.533% | -55.650% | -39.530% |
| Ardelyx Inc. | 28.120% | 34.723% | 18.969% | 89.624% | 39.758% | 44.250% | - |
| Evolus Inc | 10.280% | 12.381% | -5.600% | 60.544% | 30.387% | 60.544% | - |
| Salarius Pharmaceuticals Inc. | 11.650% | 7.981% | 17.949% | -67.606% | -17.117% | -98.248% | -99.993% |
Comments
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $10.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.
Show more
Ratings data for BCRX provided by MarketBeat